Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY

(HZNP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Horizon Therapeutics Public : BMO Capital Adjusts Horizon Therapeutics' Price Target to $132 From $118, Keeps Outperform Rating

08/05/2021 | 08:40am EST


ę MT Newswires 2021
All news about HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
01/11Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use..
AQ
01/10Horizon Therapeutics Seeks to Expand Indication for Uncontrolled Gout Medicine Krystexx..
MT
01/10Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use..
BU
01/062022 Could be a Banner Year for Biotech Stocks as per top managers (SPRC, HOTH, NLSP, P..
AQ
01/06Horizon Therapeutics plc Announces Significant Expansion of East Coast Research and Dev..
BU
01/06Horizon Therapeutics plc Announces Significant Expansion of East Coast Research and Dev..
CI
2021Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
BU
2021Horizon Therapeutics Working With Alpine Immune Sciences to Develop Therapies for Autoi..
MT
2021HORIZON THERAPEUTICS PUBLIC LTD CO : Regulation FD Disclosure (form 8-K)
AQ
2021Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Coll..
BU
More news
Analyst Recommendations on HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
More recommendations
Financials (USD)
Sales 2021 3 200 M - -
Net income 2021 542 M - -
Net Debt 2021 1 151 M - -
P/E ratio 2021 58,0x
Yield 2021 -
Capitalization 19 602 M 19 602 M -
EV / Sales 2021 6,49x
EV / Sales 2022 4,91x
Nbr of Employees 1 805
Free-Float 97,8%
Chart HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Duration : Period :
Horizon Therapeutics Public Limited Company Technical Analysis Chart | HZNP | IE00BQPVQZ61 | MarketScreener
Technical analysis trends HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 86,42 $
Average target price 141,33 $
Spread / Average Target 63,5%
EPS Revisions
Managers and Directors
Timothy P. Walbert Chairman, President & Chief Executive Officer
Paul W. Hoelscher Chief Financial Officer & Executive Vice President
Jeffrey W. Sherman CMO, Executive VP-Development & Regulatory Affairs
Jeffrey D. Kent Executive VP-Medical Affairs & Outcomes Research
Karin Rosen Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY-19.80%19 602
JOHNSON & JOHNSON-3.62%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-12.00%220 356